원발부위 불명암에 대한 EAP-II(etoposide, adriamycin, cisplatin) 복합화학요법
EAP-II(etoposide, adriamycin, cisplatin) Combination Chemotherapy for Metastatic Cancer of Unknown Orgin
대한암학회지 1994년 26권 1호 p.119 ~ 126
소속 상세정보
전의건
최지영/윤환중/길준영/조덕연/김삼용
KMID : 0360319940260010119
Abstract
Background: Optimal management of patients with metastatic cancer of unknown origin (MUO) requires appropriate clinical and pathologic evaluation to identify treatable subgroups and administer specific therapy for each patients subgroup. But, the
best
treatment in a large population of patients with MUO still remain a problem.
Cisplatin-based combination chemotherapy has not been completely studied in Korea. A total of 14 patients with metastatic cancer of unknown origin were studied to evaluate the effectiveness and toxicity of EAP-Ⅱcombination chemotherapy.
Methods: All patients were treated with etoposide 20mg/㎡ continous Ⅳ on Day 1-5, Adriamvcin 10mg/㎡ bolus on Day 1, 5 and cisplatin 20mg/㎡ continous Ⅳ on Day 1-5, every 4 weeks.
Results: Of 12 patients evaluable for response, 1(8%) had complete response and 6(50%) showed partial response with a objective response rate of 58%. The median duration of response was 9.7(8-20)months and the median survival of all patients was
15.5(4-25)months.
In the analysis of the response according to various characteristics of the patients, there was no significant difference according to various parameters(p>0.05).
Toxicity was generally mild. Whereas nausea and vomiting were mild, neuropathy was the dose limiting toxicity.
Conclusion: This study indicates that EAP-Ⅱregimen is an active therapy against metastatic cancer of unknown origin but is associated with significant neurotoxicity. Less toxic and more effective treatment protocol is anticipated.
키워드
원문 및 링크아웃 정보
등재저널 정보